Salz David A, Pitcher John D, Hsu Jason, Regillo Carl D, Fineman Mitchell S, Elliott Kevin S, Vander James F, Fischer David H, Spirn Marc J
Ophthalmic Surg Lasers Imaging Retina. 2015 Apr;46(4):439-44. doi: 10.3928/23258160-20150422-06.
To evaluate the effect of oral eplerenone on subretinal fluid, visual acuity, and choroidal thickness in patients with chronic central serous chorioretinopathy (CSCR).
Retrospective review of all patients (14 eyes of 14 patients) monitored for a minimum of 3 months with chronic CSCR who were treated with oral eplerenone in a single multi-physician retina practice. Visual acuity, dilated funduscopic examination, and spectral-domain ocular coherence tomography (OCT) with enhanced depth imaging (EDI) were obtained at each visit. Measurement of subfoveal fluid (SFF) height and choroidal thickness were performed. Two-tailed paired t test was used to calculate statistical significance of pre- and post-treatment variables.
At 1 month, 10 of 14 eyes had decreased SFF height on OCT and two eyes had complete resolution of SFF. Mean SFF height decreased from 130 µm to 62 µm (P = .05). Mean choroidal thickness decreased from 315 µm to 282 µm (P = .07). Mean visual acuity improved from logMAR 0.41 to 0.40. At 3 months, 13 of 14 (93%) had decreased SFF on OCT, and nine eyes (64%) had complete resolution of SFF. Mean SFF height decreased to 21 µm (P = .004). Mean choroidal thickness decreased to 253 µm (P = .10). Mean visual acuity improved to logMAR 0.28 (P = .02).
Oral eplerenone may be effective in treating patients with chronic CSCR.
评估口服依普利酮对慢性中心性浆液性脉络膜视网膜病变（CSCR）患者视网膜下液、视力及脉络膜厚度的影响。
回顾性分析在单一多医生视网膜诊所接受口服依普利酮治疗的所有慢性CSCR患者（14例患者的14只眼），这些患者至少接受了3个月的监测。每次就诊时均进行视力检查、散瞳眼底检查以及采用增强深度成像（EDI）的光谱域光学相干断层扫描（OCT）。测量黄斑中心凹下液（SFF）高度及脉络膜厚度。采用双侧配对t检验计算治疗前后变量的统计学显著性。
1个月时，14只眼中有10只眼的OCT显示SFF高度降低，2只眼的SFF完全消退。SFF平均高度从130 µm降至62 µm（P = 0.05）。脉络膜平均厚度从315 µm降至282 µm（P = 0.07）。平均视力从logMAR 0.41提高至0.40。3个月时，14只眼中有13只眼（93%）的OCT显示SFF降低，9只眼（64%）的SFF完全消退。SFF平均高度降至21 µm（P = 0.004）。脉络膜平均厚度降至253 µm（P = 0.10）。平均视力提高至logMAR 0.28（P = 0.02）。
口服依普利酮可能对慢性CSCR患者有效。
